United Therapeutics (UTHR) CEO Rothblatt Buys $1.3M of Stock
CEO Martine Rothblatt acquired 9,500 shares of United Therapeutics, reflecting her confidence in the company's future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Martine Rothblatt, Chairperson & CEO at United Therapeutics Corporation ($UTHR), bought 9,500 shares at an average price of $138.67, worth about $1.32 million, on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $UTHR is up 1.2% after 1 week, down 2.1% after 1 month and down 1.0% to date (from the $538.30 close on Jun 22, 2026).
UTHR
United Therapeutics Corporation
Key Points
- On June 22, 2026, Martine Rothblatt bought 9,500 shares of United Therapeutics for about $1.32 million, at a price of $138.67 each.
- The stock was trading at $546.93 recently, well above its 52-week low of $409.07 and near its high of $609.35.
- Analysts currently maintain a 'buy' recommendation for United Therapeutics, with a target mean price of $664.33.
Get $UTHR trade alerts by text
We text you when insiders, Congress or big funds trade $UTHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
Martine Rothblatt's Recent Share Purchase
On June 22, 2026, Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), bought 9,500 shares for about $1.32 million. This purchase came at an average price of $138.67 per share. The transaction reflects Rothblatt's ongoing confidence in the company's direction and future potential.
Insider Buying and Selling at United Therapeutics Corporation
This isn't the first time Rothblatt has been active in the market recently. Just a few days earlier, on June 25, she purchased another 9,500 shares at $135.42 each, totaling approximately $1.29 million. Additionally, on June 26, she sold 9,500 shares, though the details of that sale are less clear. In total, these transactions illustrate her commitment to the company amidst fluctuating market conditions.
How United Therapeutics Corporation Stock Has Traded
Currently, United Therapeutics shares are trading around $546.93, significantly above their 52-week low of $409.07 and close to the 52-week high of $609.35. The stock's performance has been relatively strong, especially considering its moving averages, with the 50-day moving average at $515.58 and the 200-day at $524.45. This recent activity by Rothblatt comes as analysts remain optimistic about the company's prospects.
Analysts Set New Price Targets
Analysts have generally maintained a positive outlook for United Therapeutics. On October 8, 2026, RBC Capital maintained an 'Outperform' rating with a target price of $708. This follows an upgrade from BTIG on October 1, which rated the stock as a 'Buy' with a target of $728. Meanwhile, Morgan Stanley has a target of $566 and maintains an 'Equal-Weight' rating.
What United Therapeutics Corporation Does
United Therapeutics focuses on developing and commercializing products for patients with chronic and life-threatening diseases. The company is known for its innovative therapies, including treatments for pulmonary arterial hypertension and neuroblastoma. Rothblatt's recent acquisitions suggest she believes in the company's ongoing projects and their potential for success in the healthcare market.
What's Ahead for United Therapeutics Corporation
Investors will be watching United Therapeutics closely, especially with the next earnings report scheduled for October 28, 2026. As always, keep in mind that Rothblatt's recent trades are reported under the STOCK Act, reflecting her confidence in the company's future. The latest Form 13F filings provide a snapshot of insider activity, but these holdings may change over time.
Related Filing Alerts
Source: Martine Rothblatt's Form 4 filing on $UTHR (Jun 22, 2026). Find the original filing: UTHR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts